Sunday, March 19, 2017

ACC: Factor Xa Inhibitor Plus P2Y12 Inhibitor OK in ACS (CME/CE)

(MedPage Today) -- But results from phase II trial should not change practice
via ACC: Factor Xa Inhibitor Plus P2Y12 Inhibitor OK in ACS (CME/CE)
by

No comments:

Post a Comment